News

Cerillo® Announces Partnership with Opentrons to Deliver Automated Microbiome Research Solutions

Cerillo®, a technology company developing advanced research platforms for microbiome studies, today announced a partnership with Opentrons Labworks, Inc., a leading force in lab automation. The collaboration not only grants researchers access to entry-level lab automation but also extends the reach of Cerillo’s comprehensive suite of microbiome research tools, fostering standardization and efficiency in laboratory processes .

Cerillo and Opentrons are automating microbiome research and the discovery of microbiome therapeutics by seamlessly integrating Cerillo’s miniaturized Alto™ and Stratus® microplate readers onto the OT-2 and Flex for deck ELISA and cell growth analysis. This integration enables easy setup of experiments, including bacterial co­culture studies with Cerillo’s Co-culture platform.

According to Eric Mayton, CEO of Cerillo, “The integration of Cerillo’s products with Opentrons’ platforms aligns with our mission to provide accessible, cost effective, user-friendly laboratory tools that efficiently standardize global microbiome research at the bench. Our alignment with Opentrons’ open-source robotics platform sets new standards for industry efficiency.”

Cerillo’s Microbiome Discovery Platform

The Cerillo Microbiome Discovery Platform offers a comprehensive suite of tools to tackle the challenges of microbiome research head-on. This interconnected platform introduces unprecedented efficiencies, elevating data standardization, reproducibility, and analysis of research findings. Cerillo’s innovative platform includes:

Co-Culture Duet System®: Cerillo’s off-the-shelf microbial interaction platform features duets with porous barriers, allowing researchers to physically isolate populations while maintaining fluidic contact. This enables the observation, study, and growth measurement of individual microbial populations alongside others.

Miniaturized Microplate Readers: Cerillo’s compact microplate readers, like the next-generation Alto™, are ten times smaller than standard ones, perfect for monitoring measurements in tight spaces and anaerobic chambers. Alto is also Ideal for ELISA and high-throughput microbial growth curve applications.

Canopy Wireless Accessory Package: Cerillo’s revolutionary SaaS package offers wireless capabilities and robust software analytics so that researchers can experience real-time data visualization, monitoring, and wireless control of their microplate readers and scale their experiments by connecting multiple readers simultaneously.

 

Learn more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin